Melatonin for the treatment of handicapped children with severe sleep disorders

Area of Science:

• Pediatric Neurology
• Sleep Medicine
• Pharmacology

Background:

• Sleep disorders are prevalent in children with intellectual and developmental disabilities.
• Existing treatments for these sleep disorders have shown limited efficacy.
• Melatonin is a natural compound increasingly used for sleep disturbances.

Purpose of the Study:

• To evaluate the efficacy and safety of melatonin in treating circadian rhythm sleep disorder in handicapped children.
• To assess the impact of melatonin on sleep parameters in this population.

Main Methods:

• An open, prospective trial involving 10 children (ages 1-11) with diagnosed circadian rhythm sleep disorder.
• Children had a history of sleep disorder for at least 6 months and prior treatment failure.
• 3-mg bedtime melatonin was administered, with response measured by sleep duration, awakenings, sleep onset latency, and early morning arousals over 4-12 months.

Main Results:

• 80% of children experienced a dramatic improvement in sleep patterns.
• Significant positive changes were observed in average hours asleep, reduced nighttime awakenings, and fewer nights with delayed sleep onset or early morning arousals.
• No adverse side effects were reported during the trial.

Conclusions:

• Melatonin is a safe, well-tolerated, and effective treatment for severe circadian rhythm sleep disorder in children with intellectual and developmental disabilities.
• The drug is relatively inexpensive and demonstrates minimal side effects.
• Wider clinical use of melatonin for this patient group is recommended.